Finnish🇫🇮 (Orion)innovation darolutamide(Nubeqa) was/is kind of s "game changer" treating prostate cancer. Also finnish🇫🇮 innovation (Orion) Opevesostat(MK-5684/ODM-208) is now on phase 3 study.It is likely to become new "game changer" for pca drug.Merck🇺🇲 and Orion 🇫🇮Announced Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Hope..Opevesostat (MK-5684; ODM-208).... - Advanced Prostate...
Hope..Opevesostat (MK-5684; ODM-208).Phase 3.
Written by
petrig
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Should go into the OMAHA2a ODM-208 (MK-5684-004): phase 3 trial?
I had my 3 monthly OC visit last week. Blood test is showing 0.3 up from 0.15 six weeks ago. MO...
PARP inhibitor Olaparib, phase 3 study findings (PROpel)
While we wait for the next generation PARP inhibitors to become available (I have written about it...
VERU Inc.
Just got back from my monthly doctor visit. My research doc was at the American Urologic...
Bipolar Androgen Therapy [BAT] & CRPC - Sam Denmeade, Hopkins.
Presentation at the 20th Annual Meeting of the Society of Urologic Oncology (SUO), Dec 04 - 06,...
Proton pump inhibitor (PPI) use may attenuate the effect of abiraterone acetate plus prednisone (AAP) in metastatic prostate cancer
Proton pump inhibitors (PPIs) are a class of medications that reduce stomach acid production. They...
Related Posts
1/4 dose enzalutamide for MCRPc working for 4 years in 87 yr. old
Merck aims for prostate cancer dominance with 3 new phase 3 Keytruda studies
FDA Fast Track Designation for 225Ac-FL-020 for mCRPCa
Depression from 2nd-generation hormone therapy is worse
177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve mCRPC: a randomized, controlled, phase 2 non inferiority trial.
